Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets

Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets Ahmedabad, 23 January, 2021 Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg (US RLD: Cytomel Tablets). Liothyronine is a man -made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland . The drug will be manufacture d at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗